Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares OutstandingWages, Salaries and Other
Ratios

Rhythm Pharmaceuticals (RYTM) Long-Term Debt Repayments (2023 - 2025)

Historic Long-Term Debt Repayments for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Q3 2025 value amounting to $5.6 million.

  • Rhythm Pharmaceuticals' Long-Term Debt Repayments rose 6696.64% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 5708.04%. This contributed to the annual value of $12.9 million for FY2024, which is 7437.15% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Long-Term Debt Repayments of $5.6 million as of Q3 2025, which was up 6696.64% from $4.3 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Long-Term Debt Repayments peaked at $5.6 million during Q3 2025, and registered a low of $1.3 million during Q2 2023.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Long-Term Debt Repayments value was $3.0 million (recorded in 2024), while the average stood at $3.2 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Long-Term Debt Repayments skyrocketed by 12764.17% in 2024 and then surged by 4571.14% in 2025.
  • Rhythm Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at $2.6 million in 2023, then skyrocketed by 47.94% to $3.8 million in 2024, then skyrocketed by 46.27% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $4.3 million for Q2 2025, and $4.6 million during Q1 2025.